Complete 2013-14 Induced Pluripotent Stem Cell (iPSC) Industry Report

Published: February 2014
No. of Pages: 127

The burgeoning iPSC product market lures major industry competitors with double-digit growth and massive change in 2013.

Stem cell research and experimentation has been in process for well over five decades, as stem cells have the unique ability to divide and replicate repeatedly. In addition, their “unspecialized” nature allows them to differentiate into a wide variety of specialized cell types. The possibilities arising from these characteristics have caused great commercial interest, with potential applications ranging from the use of stem cells in reversal or treatment of disease, to targeted cell therapy, tissue regeneration, pharmacological testing on cell-specific tissues, and more. Diseases such as Huntington’s Chorea, Parkinson’s Disease, and spinal cord injuries are examples of clinical applications in which stem cells could offer benefits in halting or even reversing damage.

Traditionally, scientists have worked with both embryonic and adult stem cells as research tools. While the appeal of embryonic cells has been their ability to differentiate into any type of cell, there has been significant ethical, moral and spiritual controversy surrounding their use for research purposes. Although some adult stem cells do have differentiation capacity, it is often limited in nature, which creates narrow options for use. Thus, induced pluripotent stem cells represent a promising combination of adult and embryonic stem cell characteristics.


Groundbreaking experimentation in 2006 led to the introduction of induced pluripotent stem cells (iPSC). These are adult cells which are isolated and then transformed into embryonic-like stem cells through the manipulation of gene expression, as well as other methods. Research and experimentation using mouse cells at Kyoto University in Japan was the first instance in which there was successful generation of the iPSC. In 2007, a series of follow-up experiments were done at Kyoto University in which human adult cells were transformed into iPSC cells.

While there has been continued excitement at the prospect of what such artificially re-manufactured cells could contribute to medical advances, there have also been issues along the way. By 2010, there were a number of private companies that were ready to capitalize on the breakthrough technology that iPSCs represent. One such company, Advanced Cell Technology in Worcester, Massachusetts, discovered several problematic issues while conducting experiments for the purpose of applying for U.S. Food and Drug Administration approval to use iPSCs in therapeutic applications. Concerns such as premature cell death, mutation into cancer cells, and low proliferation rates were some of the problems that surfaced.

Furthermore, the past twelve months have been a time of massive change for the industry. 2013 was the first year in which clinical research involving transplant of iPSCs into humans was initiated, with Masayo Takahashi of the RIKEN Center in Japan investigating the safety of iPSC-derived cell sheets in patients with macular degeneration. In another landmark event, Cellular Dynamics International (CDI) went public in July 2013 with a offering that raised $43 million dollars for the company, securing the company's position as the global leader in producing high-quality human iPSCs and differentiated cells in industrial quantities. In March of 2013, Celullar Dynamics International and the Coriell Institute for Medical Research announced receiving multi-million dollars grants from the California Institute for Regenerative Medicine (CIRM) for the creation of iPSC lines from 3,000 healthy and diseased donors, a result that will create the world’s largest human iPSC bank.

2013 represents a major year for advances in clinical research applications, production and differentiation technologies, and biobanking of iPSCs. It is clear that iPSCs are a vital research trend within the scientific community.

Research Advances:

Continued research and experimentation has resulted in numerous advances over the last few years. In one example, the University of Michigan announced in “Circulation Research” (2012) that they had developed innovative methods for use of induced pluripotent stem cells derived from skin biopsies to create cardiac muscle cells. This accomplishment quickly fueled other research into the use of iPSCs for the reversal and repair of diseased heart tissue.

Similar advances will continue to be perfected for use of reprogrammed adult cells in the treatment of other diseases and disorders. Original techniques for iPSC production, such as viral induced transcription processes, are being replaced with newer technologies as private industries join with the scientific community to develop safe and efficient methods of iPSC production. With sustained research and experimentation, established guidelines for effective production of iPSCs will be commonplace.

In summary, induced pluripotent stem cells represent a promising tool for use in the reversal and repair of many previously incurable diseases.

Market Metrics - iPSC Research Products:

For this reason a large and thriving research products market has grown into existence for the cell type. The number of iPSC research products sold worldwide has been growing at an annual rate of 14.7% for the past five years. In addition, 22% of all stem cell researchers now self-report as having used induced pluripotent stem cells within a research project. It is clear that iPSCs are a vital research trend within the scientific community.

A distinctive feature of this report is an end-user survey of 274 researchers (131 U.S. / 143 International) that identify as having induced pluripotent stem cells as their core research focus. These survey findings reveal iPSC researcher needs, technical preferences, key factors influencing buying decisions, and more. They can be used to make effective product development decisions, create targeted marketing messages, and produce higher prospect-to-client conversion rates.

Remember, to benefit from this lucrative product market, you need to anticipate and serve the needs of your clients, or your competitors will.

Key Findings Include:

  • Charts, Timelines, and Financials for the iPSC Research Product Market
  • Trends for iPSC Grants, Scientific Publications, and Patents
  • 5-Year Market Size Projections (2014-2018)
  • Competitive Environment Analysis, including Market Share by Competitor
  • Preferred Species for iPSC Research
  • iPSC Product Categories (Breakdown of Market Share by Each)
  • Consumer Behavioral Patterns and Preferred Providers
  • Crucial Trends and Unmet Market Needs
  • “Tested Sentences” for Selling to iPSC Scientists
  • Breakdown of the Marketing Methods Used by Industry Participants
  • End-User Survey of iPSC Researchers (131 U.S. / 143 International)

In summary, this is a must-read industry report for research supply companies to optimally position themselves to sell iPSC products. To profit from this lucrative and rapidly expanding market, you need to understand your key strengths relative to the competition, intelligently position your products to fill gaps in the marketplace, and take advantage of crucial iPSC trends. Claim this report now to profit from this expanding market - or your competition will.

Complete 2013-14 Induced Pluripotent Stem Cell (iPSC) Industry Report

Table Of Contents
I. Abstract

II. iPSC cells Background
A. Definition
B. Discovery
C. Advantages & Disadvantages

III. Timeline
A. Production of iPSC cells (Key Events)
B. Full Timeline of Events

IV. iPSC cells Market Research Applications
A. Pharmaco-Toxicological Screening
B. Disease Modeling
C. Autologous Cell Transplantation
D. Breakdown of iPSC cells Research, By Applied Research Application

V. Characterization Of iPSC cells Research Advances
A. Methods of Making iPSC cells – Comparison of Methods by Downstream Application
B. Summary of iPSC cells Derivation Methods, by Cell Type
C. Diseases in Which iSPCs Have Been Derived from Patients

VI. Companies Selling iPSC cells Research Products
A. List of Companies
B. Rate of Entrants by Year

VII. Types Of Induced Pluripotent Stem Cells Research Products
A. Stem Cell Product Categories
B. iPSC cells Market Share Breakdown, By Product Area

VIII. Companies Developing iPSC cells Therapies
A. Commerical Entities
1. ViaCyte
2. Fate Therapeutic
3. iPerian
4. Cellular Dynamics
5. Mesoblast
B. Non-Commercial Organizations Developing iPSC cells Therapies

IX. Strategic Collaborations For Development Of Induced Pluripotent Stem Cells Products
A. Life Technologies
B. Lonza Group AG
C. EMD Millipore
D. Sigma Aldrich
E. Roslin Cells, Ltd.
F. ArunA Biomedical
G. CeeTox and Cellular Dynamics

X. iPSC cells Market Trend Analysis
A. Clinical Trials
B. Grant Analysis
1. Historical Analysis
2. Future 5-Year Projection
C. Patent Analysis
D. Scientific Publication Analysis
1. Historical Data
2. Future 5-Year Projections
3. Comparison of Induced Pluripotent Stem Cells Research Frequency, Relative to Other Cell Types
E. Search Phrase Analysis
1. Induced Pluripotent Stem Cell Search Terms
2. Induced Pluripotent Stem Cell “Google” Search Analysis
F. Geographical Analysis: Domestic vs. International Status
1. Number of iPSC cells Labs, by Region of World
2. Percent of Total iPSC cells -Specific Research Funding, by Region of World
G. Additional Sources of iPSC cells Research Funding

XI. Induced Pluripotent Stem Cells Market Size
A. Definition: iPSC cells Research Products
B. Experimental Approach
C. iPSC cells Research Products, Market Size
D. iPSC cells Research Products, 5-Year Market Projections

XII. Scientist Panel: Induced Pluripotent Stem Cells Detailed End-User Survey
A. Survey Overview
B. Characterization of Market Survey Respondents
1. Geographic Distribution of Respondents
2. Respondent Breakdown by Industry Affiliation
3. Breakdown of Respondents by Duration of iPSC cells Research Activity
C. Survey Findings
1. General Scope
2. Comparison of Providers / Brand Preferences
3. Marketing Assessment
D. Terms Used in Online Product Search

XIII. Strategies For Accessing The Marketplace
A. Top Research Institutions Performing Stem Cell Research
1. University of Wisconsin, including WARF, WiCell, and the WISC Bank
2. US National Institutes of Health (NIH)
3. Johns Hopkins University
4. California Institute for Regenerative Medicine
5. University of Connecticut Induced Pluripotent Stem Cells Core (iPSCC)
B. Events of Interest (2013-14)

XIV. Conclusions

Published By: BioInformant Worldwide, L.L.C.
Product Code: BioInformant Worldwide, L.L.C.1011

Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we’ll share relevant market report titles for you to explore.

Related Reports:


  • 400,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Biotechnology market as per your needs. Get the best of Biotechnology research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest:

Live Chat
Live Chat by Comm100